Announcements Trials
Browse Landscape

Status

Recruiting 2Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2

Sponsor

Cancer Type

Dermatologic 2Gastrointestinal 1

Conditions

Neoplasms 8Colorectal Neoplasms 7Prostatic Neoplasms 6Stomach Neoplasms 5Lung Neoplasms 5Breast Neoplasms 5Endometrial Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Sarcoma 3Pancreatic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Oropharyngeal Neoplasms 2Obesity 2Meningioma 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Esophageal Neoplasms 2Disease 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Carcinoma, Basal Cell 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Surgical Wound Dehiscence 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Small Cell Lung Carcinoma 1Skull Base Neoplasms 1Skin Neoplasms 1Salivary Gland Neoplasms 1

Interventions

pembrolizumab 54Nivolumab 51Ipilimumab 29Cyclophosphamide 16binimetinib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10fludarabine 9Radiosurgery 9relatlimab 8encorafenib 8Opdualag 8Interleukin-2 8Biopsy 8aldesleukin 7Blood Specimen Collection 7atezolizumab 6Immunotherapy 6cemiplimab 5CTLA-4 Antigen 5Bevacizumab 5trametinib 4dabrafenib 4Temozolomide 4Paclitaxel 4Immune Checkpoint Inhibitors 4spartalizumab 3fludarabine phosphate 3Surgical Procedures, Operative 3Metformin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Melanoma × Observation × Clear all
NCT06887348 2026-01-12

RPx

Replimune, Inc.

Recruiting
50 enrolled
DermatologicGastrointestinal

Carcinoma, Hepatocellular, Melanoma

NCT07092670 2025-09-05

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

Intergruppo Melanoma Italiano

Recruiting
270 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡